Dong Xi
Dong Xi
Verified email at novartis.com
Title
Cited by
Cited by
Year
Public face and private thrift in C hinese consumer behaviour
L Lin, D Xi, RM Lueptow
International journal of consumer studies 37 (5), 538-545, 2013
342013
A class of improved hybrid Hochberg–Hommel type step-up multiple test procedures
J Gou, AC Tamhane, D Xi, D Rom
Biometrika 101 (4), 899-911, 2014
282014
Allocating recycled significance levels in group sequential procedures for multiple endpoints
D Xi, AC Tamhane
Biometrical Journal 57 (1), 90-107, 2015
242015
Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?
CU Kunz, S Jörgens, F Bretz, N Stallard, K Van Lancker, D Xi, S Zohar, ...
Statistics in Biopharmaceutical Research 12 (4), 461-477, 2020
132020
A unified framework for weighted parametric multiple test procedures
D Xi, E Glimm, W Maurer, F Bretz
Biometrical Journal 59 (5), 918-931, 2017
112017
Hierarchical testing of a primary and a secondary endpoint in a group sequential design with different information times
J Gou, D Xi
Statistics in Biopharmaceutical Research 11 (4), 398-406, 2019
92019
A general multistage procedure for k‐out‐of‐n gatekeeping
D Xi, AC Tamhane
Statistics in medicine 33 (8), 1321-1335, 2014
92014
On the optimal timing of futility interim analyses
D Xi, P Gallo, D Ohlssen
Statistics in Biopharmaceutical Research 9 (3), 293-301, 2017
72017
Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials
M Akacha, J Branson, F Bretz, B Dharan, P Gallo, I Gathmann, ...
Statistics in Biopharmaceutical Research 12 (4), 419-426, 2020
62020
Optimal exact tests for multiple binary endpoints
R Ristl, D Xi, E Glimm, M Posch
Computational Statistics & Data Analysis 122, 1-17, 2018
62018
Seamless phase IIa/IIb and enhanced dose-finding adaptive design
J Yuan, H Pang, T Tong, D Xi, W Guo, P Mesenbrink
Journal of biopharmaceutical statistics 26 (5), 912-923, 2016
52016
Replicability, Reproducibility, and Multiplicity in Drug Development
F Bretz, W Maurer, D Xi
CHANCE 32 (4), 4-11, 2019
32019
Symmetric graphs for equally weighted tests, with application to the Hochberg procedure
D Xi, F Bretz
Statistics in medicine 38 (27), 5268-5282, 2019
22019
Multiplicity
D Xi, E Glimm, F Bretz
Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis, 2016
22016
An additive boundary for group sequential designs with connection to conditional error
D Xi, P Gallo
Statistics in medicine 38 (23), 4656-4669, 2019
12019
“Step-Down Parametric Procedures for Testing Correlated Endpoints in a Group-Sequential Trial” by Yiyong Fu
M Wolbers, E Glimm, D Xi
Statistics in Biopharmaceutical Research 11 (1), 104-105, 2019
12019
Multiple Comparisons, Multiple Primary Endpoints and Subpopulation Analysis
E Glimm, D Xi, P Gallo
Textbook of Clinical Trials in Oncology: A Statistical Perspective, 183, 2019
2019
Commentary on “Statistics at FDA: Reflections on the Past Six Years”
F Bretz, D Xi
Statistics in Biopharmaceutical Research 11 (1), 20-25, 2019
2019
An introduction to graphical multiple testing in confirmatory clinical trials
D Xi
ASA Biopharmaceutical Report 23 (1), 3-6, 2016
2016
Topics in Gatekeeping and Group Sequential Procedures for Multiple Endpoints
D Xi
Northwestern University, 2013
2013
The system can't perform the operation now. Try again later.
Articles 1–20